[Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene]
/in International Publications, Malignant Melanoma /von 2004-08-01 / Ai Zheng 2004 Aug;23(8):910-3High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules
/in International Publications, Newcastle Disease Virus /von 2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-302Autologous dendritic cell vaccines for non-small-cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2004-07-15 / J. Clin. Oncol. 2004 Jul;22(14):2808-15Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2004-07-15 / Cancer Res. 2004 Jul;64(14):4973-9Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-07-15 / Clin. Cancer Res. 2004 Jul;10(14):4699-708Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients
/in International Publications, Malignant Melanoma /von 2004-07-10 / Int. J. Cancer 2004 Jul;110(5):730-40Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma
/in Gallbladder Cancer, International Publications /von 2004-07-01 / Hum. Pathol. 2004 Jul;35(7):881-6Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2004-07-01 / Leuk. Lymphoma 2004 Jul;45(7):1419-28Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-06-08 / Cancer Immunol. Immunother. 2004 Sep;53(9):777-85
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de